U.S., March 20 -- ClinicalTrials.gov registry received information related to the study (NCT07482787) titled 'Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa' on March 04.
Brief Summary: The upcoming trial is for EB patients is a topically applied whole-body treatment of patients with either Simplex, RDEB or Junctional (nH) ages 1 month to 12 years old at study entry. There are only 4 site visits by patients with minimal assessments over a 2-month period, and patients completing this study will have the ability to continue receiving SD-101-6.0 at home in an open-label extension study. The drug product and placebo require no special preparation or storage conditions (room temperature).
Study Start Date: May 15
Study ...